Improving immune responses against aggressive B-cell lymphomas
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
This study is looking at a new treatment that helps your immune system fight diffuse large B-cell lymphoma (DLBCL) by targeting a protein called MALT1, and it may offer better results for patients like you who are receiving immunotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10929491 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immune system's ability to fight diffuse large B-cell lymphoma (DLBCL), a common and aggressive type of non-Hodgkin lymphoma. The approach involves targeting a specific protein called MALT1, which plays a crucial role in the growth of lymphoma cells and the suppression of anti-tumor immunity. By using a newly developed MALT1 inhibitor, the research aims to disrupt the signals that promote lymphoma growth and improve the effectiveness of immunotherapy treatments. Patients may be involved in trials testing this innovative treatment to see if it can lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with diffuse large B-cell lymphoma who have not responded well to existing therapies.
Not a fit: Patients with other types of lymphoma or those who have already had extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive B-cell lymphomas, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting MALT1 in other contexts, indicating potential for success in this novel application.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Zappasodi, Roberta — Weill Medical Coll of Cornell Univ
- Study coordinator: Zappasodi, Roberta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.